DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he...
Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise...
Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both...
